Palvella Therapeutics
PVLA
130.59
+2.59
+2.02%
Palvella Therapeutics
US · PVLA
#2822 by market cap
Listed 1970
130.59
+2.59
+2.02%
Live - 5344 symbols - heartbeat 438s ago
· 2026-10-08 04:00
Pre-market
131.00
+0.31%
After-hours
130.70
+0.08%
Overnight
130.05
-0.41%
- Market cap
- 1.88B
- P/E (TTM)i
- -26.93
- P/Bi
- 8.68
- EPSi
- -3.71
- Div yieldi
- 0.00%
- 52W posi
- 68%
Reader sentiment
Are you bullish or bearish on PVLA?
Anonymous reader poll. Unscientific, not investment advice.
About Palvella Therapeutics
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It develops a pipeline of treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA.
- Founded
- 2015
- CEO
- Mr. Wesley H. Kaupinen
- Employees
- 29
- Headquarters
- Wayne, Pennsylvania, United States of America
- Fiscal year end
- 12-31
- Website
- palvellatx.com
Company profile
- Exchange
- US
- Symbol
- PVLA
- Market-cap rank
- #2822
- Listing date
- 1970-01-01
- Market cap
- 1.88B
- Float cap
- 1.39B
- Shares out
- 14.41M
- Float shares
- 10.68M
Sectors & themes
Biotechnology
Quote time 2026-10-08 04:00:14 · For reference only, not investment advice and not tailored to your situation.